Vertex Pharmaceuticals Inc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.55%.
Did VRTX Beat Earnings? Q3 2025 Results
Vertex Pharmaceuticals delivered a solid beat on both the top and bottom lines in Q3 2025, with non-GAAP EPS of $4.80 clearing the $4.58 consensus by 4.87% and revenue of $3.08 billion edging past estimates by 0.56%, representing 11% growth year over year. The quarter's strength was anchored by the company's dominant cystic fibrosis franchise, with TRIKAFTA/KAFTRIO contributing $2.65 billion alone, while newer launches added meaningful momentum: ALYFTREK generated $247 million in its first year on market, JOURNAVX added $19.60 million following its March debut, and CASGEVY contributed $16.90 million as cell therapy uptake continues to build. Despite the headline beat, <a href="https://247wallst.com/investing/2025/11/03/vertex-falls-10-after-reporting-mixed-q3-results/">shares came under pressure</a> as investors weighed the pace of pipeline diversification. Looking ahead, Vertex narrowed its full-year 2025 revenue guidance to $11.90 billion to $12.00 billion and lowered its non-GAAP effective tax rate outlook to 17%-18%, while signaling increased investment in its povetacicept kidney disease program and JOURNAVX commercial expansion.
- Continued strong CF patient demand including ALYFTREK uptake
- Favorable net pricing in CF versus prior year in the U.S.
- Early contributions from CASGEVY and JOURNAVX launches
- Solid international performance across multiple geographies
“Vertex delivered strong results across the board in the third quarter, extending our leadership in CF, continuing to build global momentum for CASGEVY, and advancing the launch of JOURNAVX in acute pain.”
Vertex Pharmaceuticals CEO, on the earnings call
Forward Guidance & Outlook
Vertex refined full year 2025 guidance with total revenue now expected to be $11.9 to $12.0 billion (narrowed from $11.85 to $12.0 billion), assuming continued CF growth including global ALYFTREK launch, continued CASGEVY uptake, and early JOURNAVX contributions. Combined non-GAAP R&D, AIPR&D, and SG&A expenses now expected to be $5.0 to $5.1 billion (increased from $4.9 to $5.0 billion), reflecting acceleration of povetacicept programs and increased JOURNAVX commercial investment. Non-GAAP effective tax rate guidance was lowered to 17% to 18% from 20.5% to 21.5%, incorporating one-time tax benefits including Alpine-related R&D tax credits and anticipated recognition of deferred tax benefits. Tariff cost impact expected to be immaterial in 2025.
VRTX YoY Financials
VRTX Revenue by Segment
VRTX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.